Bristol-Myers Squibb completes previously announced sale of its HIV R&D portfolio to ViiV Healthcare
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced sale of its HIV R&D portfolio to ViiV Healthcare, which includes a number of programs at different stages of discovery, preclinical and clinical development.
Brilique (ticagrelor) approved in EU for extended treatment of patients with history of heart attack
- Details
- Category: AstraZeneca
AstraZeneca today announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
- Details
- Category: Novartis
Alcon, the global leader in eye care and a division of Novartis, announced today that it has entered into an agreement to acquire Transcend Medical, Inc., a privately-held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma.
U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM) for the treatment of people with primary progressive multiple sclerosis (PPMS).
Bristol-Myers Squibb and Dana-Farber Cancer Institute enter into a collaboration agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Dana-Farber Cancer Institute today announced that they have entered into a research collaboration agreement as part of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration
- Details
- Category: UCB
UCB and Baylor College of Medicine announced that they have started a strategic research alliance, led at Baylor by Professor Huda Zoghbi, that aims to discover new therapeutics to treat neurodegenerative disease.
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
- Details
- Category: Novartis
Sandoz, a Novartis company and the global leader in biosimilars, announced today that the European Medicines Agency (EMA) has accepted their Marketing Authorization Application (MAA) for its biosimilar to Amgen's EU-licensed Neulasta®* (pegfilgrastim) - a long-acting recombinant human granulocyte colony-stimulating factor (G-CSF).
More Pharma News ...
- Bayer continues to grow its open innovation activities
- Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction
- Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals
- Bristol-Myers Squibb Foundation awards eight grants totaling nearly $11.5M to make lung and skin cancer screening
- Abbott to Acquire Alere, becoming leader in point of care testing
- Merck announces new biopharma heads for North America and China
- European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable